Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerance of Therapeutic BCG in Postoperative NMIBC
NCT06350838Phase 1Completed
- Sponsor
- Chengdu Coen Biotechnology
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Chengdu Coen Biotechnology. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and serious Treatment-Emergent Adverse Events at 6 weeks, Effects on clinical laboratory tests index of blood biochemistry at 6 weeks and 7 more. Started Nov 2022; status: completed.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06350838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350838.